PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies

Esophageal cancer ranks as the seventh leading cause of cancer globally, with 604,100 new cases, and the sixth leading cause of cancer-related deaths worldwide. When applicable, surgery is the gold standard treatment for resectable oesophageal-esophagogastric junction cancer. The surgical technique requires both an abdominal approach and a transthoracic approach to resect the esophagus, perform the anastomosis, and allow optimal lymph node removal. Surgery Historically, esophagectomy was performed entirely through open surgery. This procedure was complex, associated with significant morbidit

Trial Details

NCT ID
NCT07434739
Phase
NA
Sponsor
University Hospital, Lille
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • paravertebral catheter analgesia
  • Epidural group
Locations (sample)
  • Lille, France|50.63391,3.05512

Key Eligibility Criteria

  • Patient requiring totally minimally invasive surgical esophagectomy (robot-assisted or not) with 2 Ivor-Lewis type approaches: laparoscopy for the …
  • Age ≥ 18 years old
  • Patient who has given written consent to participate in the trial
  • Socially insured patient

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →